Spots Global Cancer Trial Database for Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients
Official Title: Phase II Trial of Neoadjuvant Chemoradiation With Bevacizumab for Chinese Locally Advanced Rectal Adenocarcinoma
Study ID: NCT01554059
Conditions
Study Description
Brief Summary: The purpose of the study is to evaluate the efficacy and safety of the combination of cytotoxic chemotherapy (Oxaliplatin and 5Fu) with bevacizumab concomitantly with radiotherapy as neoadjuvant treatment for patients with locally advanced but resectable rectal adenocarcinoma.
Detailed Description: Primary endpoint: Pathological Complete Response Rate (pCR) Secondary endpoint: Time to Relapse, disease free survival, overall survival and safety data
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
